Trials / Active Not Recruiting
Active Not RecruitingNCT04469712
Non-randomized Prospective Comparison Between SASI Bipartition and RYGB
Long-term Outcomes of Bariatric Patients Treated With Gastric Bypass or Single-anastomosis Sleeve Ileal Bypass (SASI Bipartition)
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 280 (estimated)
- Sponsor
- Aleris Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main aim of this project is to assess the safety and efficiency of the SASI Bipartition.
Detailed description
The Roux-en-Y Gastric Bypass (RYGB) is the procedure of choice in morbid obesity with metabolic disorders in most of the reference centers. Recent data describes the SASI Bipartition as being as efficient on weight loss and co-morbidities as the RYGB, with the advantage of being less technically difficult and less morbidity. In order to draw definite conclusions regarding the procedure, larger series with longer follow-up are necessary. Patients with BMI over 40, or with BMI over 35 with comorbidities are offered SASI Bipartition with 300 cm common limb or standard RYGB. Follow up is performed through visits at 3, 12, 24, 36, 48, and 60 months after surgery. Results on weight loss, comorbidities resolution, complications, and need of supplements are registered.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | SASI Bipartition | SASI Bipartition is performed with a sleeve gastrectomy over a 32 French gastric bougie and a 300 cm common limb. Side-to-side gastroileostomy with a diameter of approximately 2.5 cm at the anterior part of antrum, 6 cm proximal to pylorus. |
| PROCEDURE | Gastric bypass | A small gastric pouch (15 mL) is created, and the jejunum brought up as an antecolic and antegastric fashion. Routine limb lengths were 150 cm for the alimentary limb and 60 cm for the bilio-pancreatic limb. Both mesenteric defects are closed with the Endohernia® stapler. |
Timeline
- Start date
- 2020-08-01
- Primary completion
- 2027-07-01
- Completion
- 2027-08-01
- First posted
- 2020-07-14
- Last updated
- 2025-02-06
Locations
1 site across 1 country: Norway
Source: ClinicalTrials.gov record NCT04469712. Inclusion in this directory is not an endorsement.